Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.

[1]  K. Fukuchi,et al.  Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  Ronald N. Jones,et al.  First Report of Staphylococcal Clinical Isolates in Mexico with Linezolid Resistance Caused by cfr: Evidence of In Vivo cfr Mobilization , 2010, Journal of Clinical Microbiology.

[3]  E. Protonotariou,et al.  Dissemination of two international linezolid-resistant Staphylococcus epidermidis clones in Greek hospitals. , 2010, The Journal of antimicrobial chemotherapy.

[4]  Gracia Morales,et al.  Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Robinson,et al.  Polyphyletic Emergence of Linezolid-Resistant Staphylococci in the United States , 2010, Antimicrobial Agents and Chemotherapy.

[6]  M. Bounthavong,et al.  Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis , 2010, Current medical research and opinion.

[7]  W. Rui,et al.  Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. , 2010, International journal of antimicrobial agents.

[8]  Ronald N. Jones,et al.  Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. , 2009, Diagnostic microbiology and infectious disease.

[9]  J. Mingorance,et al.  Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. , 2009, Diagnostic microbiology and infectious disease.

[10]  G. Eliopoulos.  Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. , 2009, The Journal of infection.

[11]  K. Mathiopoulos,et al.  A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of Staphylococcus epidermidis. , 2009, The Journal of antimicrobial chemotherapy.

[12]  Ronald N. Jones,et al.  ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. , 2009, Diagnostic microbiology and infectious disease.

[13]  K. Fukuchi,et al.  Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[14]  Ronald N. Jones,et al.  First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States , 2008, Antimicrobial Agents and Chemotherapy.

[15]  Ronald N. Jones,et al.  Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. , 2007, Diagnostic microbiology and infectious disease.

[16]  C. Wolz,et al.  Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium , 2007, Epidemiology and Infection.

[17]  Ronald N. Jones,et al.  Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. , 2007, International journal of antimicrobial agents.

[18]  J. Poehlsgaard,et al.  The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics , 2006, Antimicrobial Agents and Chemotherapy.

[19]  S. S. Andrade,et al.  Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. , 2006, International journal of antimicrobial agents.

[20]  Ronald N. Jones,et al.  Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. , 2006, The Journal of antimicrobial chemotherapy.

[21]  Ronald N. Jones,et al.  Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. , 2005, International journal of antimicrobial agents.

[22]  C. Kloft,et al.  Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses , 2005, Antimicrobial Agents and Chemotherapy.

[23]  Ronald N. Jones,et al.  Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. , 2005, Diagnostic microbiology and infectious disease.

[24]  H. Gold,et al.  Antimicrobial resistance to linezolid. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  G. Eliopoulos,et al.  Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. , 2004, The Journal of infectious diseases.

[26]  D. Honeybourne,et al.  Intrapulmonary penetration of linezolid. , 2003, The Journal of antimicrobial chemotherapy.

[27]  Ronald N. Jones,et al.  Linezolid Resistance since 2001: SENTRY Antimicrobial Surveillance Program , 2003, The Annals of pharmacotherapy.

[28]  G. French.  Safety and tolerability of linezolid. , 2003, The Journal of antimicrobial chemotherapy.

[29]  Ronald N. Jones,et al.  Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. , 2003, The Journal of antimicrobial chemotherapy.

[30]  R. Moellering,et al.  Linezolid: The First Oxazolidinone Antimicrobial , 2002, Annals of Internal Medicine.

[31]  R. Jones,et al.  Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  Ronald N. Jones,et al.  Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS). , 2002, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[33]  Ronald N. Jones,et al.  A multicenter evaluation of linezolid antimicrobial activity in North America. , 2002, Diagnostic microbiology and infectious disease.

[34]  Ronald N. Jones,et al.  Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. , 2002, Diagnostic microbiology and infectious disease.

[35]  Mary Jane Ferraro,et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.

[36]  Ronald N. Jones,et al.  Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. , 2001, Diagnostic microbiology and infectious disease.

[37]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[38]  D. Shinabarger.  Mechanism of action of the oxazolidinone antibacterial agents. , 1999, Expert opinion on investigational drugs.